期刊论文详细信息
Cost Effectiveness and Resource Allocation
Burden of disease and costs of aneurysmal subarachnoid haemorrhage (aSAH) in the United Kingdom
Research
Jane Wolstenholme1  Oliver Rivero-Arias1  Alastair Gray1 
[1] Health Economics Research Centre, Department of Public Health, University of Oxford, UK;
关键词: National Health Service;    Informal Care;    Aneurysmal Subarachnoid Haemorrhage;    Hospital Episode Statistics;    aSAH Patient;   
DOI  :  10.1186/1478-7547-8-6
 received in 2009-04-22, accepted in 2010-04-27,  发布年份 2010
来源: Springer
PDF
【 摘 要 】

BackgroundTo estimate life years and quality-adjusted life years (QALYs) lost and the economic burden of aneurysmal subarachnoid haemorrhage (aSAH) in the United Kingdom including healthcare and non-healthcare costs from a societal perspective.MethodsAll UK residents in 2005 with aSAH (International Classification of Diseases 10th revision (ICD-10) code I60). Sex and age-specific abridged life tables were generated for a general population and aSAH cohorts. QALYs in each cohort were calculated adjusting the life tables with health-related quality of life (HRQL) data. Healthcare costs included hospital expenditure, cerebrovascular rehabilitation, primary care and community health and social services. Non-healthcare costs included informal care and productivity losses arising from morbidity and premature death.ResultsA total of 80,356 life years and 74,807 quality-adjusted life years were estimated to be lost due to aSAH in the UK in 2005. aSAH costs the National Health Service (NHS) £168.2 million annually with hospital inpatient admissions accounting for 59%, community health and social services for 18%, aSAH-related operations for 15% and cerebrovascular rehabilitation for 6% of the total NHS estimated costs. The average per patient cost for the NHS was estimated to be £23,294. The total economic burden (including informal care and using the human capital method to estimate production losses) of a SAH in the United Kingdom was estimated to be £510 million annually.ConclusionThe economic and disease burden of aSAH in the United Kingdom is reported in this study. Decision-makers can use these results to complement other information when informing prevention policies in this field and to relate health care expenditures to disease categories.

【 授权许可】

CC BY   
© Rivero-Arias et al; licensee BioMed Central Ltd. 2010

【 预 览 】
附件列表
Files Size Format View
RO202311109633644ZK.pdf 1224KB PDF download
【 参考文献 】
  • [1]
  • [2]
  • [3]
  • [4]
  • [5]
  • [6]
  • [7]
  • [8]
  • [9]
  • [10]
  • [11]
  • [12]
  • [13]
  • [14]
  • [15]
  • [16]
  • [17]
  • [18]
  • [19]
  • [20]
  • [21]
  • [22]
  • [23]
  • [24]
  • [25]
  • [26]
  • [27]
  • [28]
  • [29]
  • [30]
  • [31]
  • [32]
  • [33]
  • [34]
  • [35]
  • [36]
  • [37]
  文献评价指标  
  下载次数:1次 浏览次数:0次